Two Chinese mRNA Covid Vaccines Move Toward Clinical Trials
(Bloomberg) --
A Chinese company said it's received approval to start clinical trials of a Covid-19 vaccine based on mRNA technology, while local media reported that another domestic company has applied to start a similar trial.
CSPC Pharmaceutical Group Ltd. has been approved by China's medical product regulator to begin a trial of an COVID-19 vaccine named “SYS6006,” it said in a statement to the Hong Kong stock exchange.
The company said pre-clinical studies demonstrated the vaccine can help neutralize against the omicron variant of coronavirus. It does not need to be stored at below-freezing temperatures, the company said.
China has inoculated the majority of its population using domestically-made coronavirus vaccines based on older inactivated virus technology, but authorities have not approved any based on mRNA outside the cities of Hong Kong and Macau.
China is battling its worst coronavirus outbreak since early 2020 as the more infectious omicron variant spreads in large cities including Shanghai.
Separately, Shanghai-based Stemirna Therapeutics has applied to Chinese regulators to conduct a clinical trial of its mRNA Covid-19 vaccine, state-media reported.
The company has built production facilities capable of producing 400 million doses a year, the Cailian financial news service reported.
A Chinese mRNA vaccine developed by Walvax Biotechnology Co., Suzhou Abogen Biosciences Co. and the Chinese military has already entered clinical trials.
But that vaccine may fall short of the benefits generated by shots from Pfizer Inc., BioNTech SE and Moderna Inc., a study published in January showed.
China National Pharmaceutical Group Co., better known as Sinopharm, said Sunday its second-generation recombinant protein Covid-19 vaccine has received approval from Beijing for clinical trials. The improved vaccine has already been approved by the United Arab Emirates as a booster shot and enhances immune response to the coronavirus, the company said in December.
©2022 Bloomberg L.P.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.
-
Navigating Energy Crossroads: S Jaishankar's Call For Diversified Supply Chains At G20 Ministerial Meeting
As geopolitical fault lines continue to test maritime trade routes and commodity flows, Jaishankar's message remains pertinent: true economic resilience requires open markets, protected transit lines, and a genuine commitment to multilateral cooperation rather than coercion.
-
Indians Are Travelling, But Not Every Journey Is A Holiday | The Week In Whys
Pilgrims, patients and working women are the real travellers, and the system hasn't quite caught up with them.
-
Getting To Work Costs Women More | The Reason Why
It is not just about women paying more than men. It is about women paying much more in cities than in villages.
-
AI Bias In Investing Cannot Be Eliminated, But It Can Be Governed
Framing is a particularly important example as identical financial information presented in terms of gains rather than losses can lead an LLM to reach a different assessment.
